CoVigi phase IV multicentric trial evaluating COVID-19
vaccination effectiveness, safety, and immune response
dynamics: SARS-CoV-2-specific antibody and T-cell response
focused on patients with gastrointestinal tumors

a 2023

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ et. al.

Basic information

Original name

CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors

Authors

OBERMANNOVÁ, Radka (203 Czech Republic, guarantor), Iveta SELINGEROVÁ (203 Czech Republic, belonging to the institution), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution), Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution) and Igor KISS (203 Czech Republic, belonging to the institution)

Edition

2023

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30230 Other clinical medicine subjects

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

RIV identification code

RIV/00216224:14110/23:00131953

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.annonc.2023.04.432

UT WoS

001037960400377

Keywords (in Czech)

COVID-19; Solid cancer; multicentric trial;

Keywords in English

COVID-19; Solid cancer; multicentric trial;

Abstract

V originále

Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.

Links

LM2023049, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ and Igor KISS. CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors. 2023. Available from: https://dx.doi.org/10.1016/j.annonc.2023.04.432.

@proceedings{2327137,
   author = {Obermannová, Radka and Selingerová, Iveta and Demlová, Regina and Valík, Dalibor and Zdražilová Dubská, Lenka and Kiss, Igor},
   doi = {http://dx.doi.org/10.1016/j.annonc.2023.04.432},
   keywords = {COVID-19; Solid cancer; multicentric trial;},
   language = {eng},
   title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors},
   url = {https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub},
   year = {2023}
}

TY  - CONF
ID  - 2327137
AU  - Obermannová, Radka - Selingerová, Iveta - Demlová, Regina - Valík, Dalibor - Zdražilová Dubská, Lenka - Kiss, Igor
PY  - 2023
TI  - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
KW  - COVID-19
KW  - Solid cancer
KW  - multicentric trial;
UR  - https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub
N2  - Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.
ER  -

OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ and Igor KISS. \textit{CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors}. 2023. Available from: https://dx.doi.org/10.1016/j.annonc.2023.04.432.

Detailed Information on Publication Record